Drug interactions between tacrolimus and clotrimazole troche: a data mining approach followed by a pharmacokinetic study
- 128 Downloads
This study investigated the effects of clotrimazole troche on the risk of transplant rejection and the pharmacokinetics of tacrolimus.
The data mining approach was used to investigate whether the use of clotrimazole increased the risk of transplant rejection in patients receiving tacrolimus therapy. Patient data were acquired from the US Food and Drug Administration’s Adverse Event Reporting System (FAERS) from the first quarter of 2004 to the end of 2017. Next, we retrospectively investigated the effect of clotrimazole troche on tacrolimus pharmacokinetics in seven patients who underwent heart transplantation between March and December 2017.
The FAERS subset data indicated a significant association between transplant rejection and tacrolimus with clotrimazole [reporting odds ratio 1.92, 95% two-sided confidence interval (95% CI) 1.43–2.58, information component 0.81, 95% CI 0.40–1.23]. The pharmacokinetic study demonstrated a significant correlation between trough concentration (C0) and area under the concentration-time curve of tacrolimus after discontinuation of clotrimazole (R2 = 0.60, P < 0.05) but not before its discontinuation. Furthermore, the median clearance/bioavailability of tacrolimus after discontinuation of clotrimazole was 2.2-fold greater than that before its discontinuation (0.27 vs. 0.59 L/h/kg, P < 0.05). The median C0 decreased from 10.7 ng/mL on the day after discontinuation of clotrimazole to 6.5 ng/mL at 1 day and 5.3 ng/mL at 2 days after its discontinuation.
Immediate dose adjustments of tacrolimus may be beneficial to avoid transplant rejection when clotrimazole troche is added or discontinued.
KeywordsTacrolimus Clotrimazole Drug interaction Transplant rejection Heart transplantation
We would like to thank all the patients who participated in this study.
Participated in research design: Uno, Wada, Hosomi, Ikura, and Takada
Conducted experiments and clinical study: Uno, Wada, Hosomi, and Takada
Performed data analysis: Uno, Wada, Hosomi, Kawase, and Takada
Wrote or contributed to the writing of the manuscript: Uno, Wada, Hosomi, Matsuda, Ikura, Takenaka, Terakawa, Oita, Yokoyama, Kawase, and Takada
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
This study was approved by the local ethics committee of the National Cerebral and Cardiovascular Center.
This study was a retrospective observational study, and informed consent to participate was obtained via the opt-out method.
- 1.Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM (2010) Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50(8):1101–1111PubMedGoogle Scholar
- 19.El-Asmar J, Gonzalez R, Bookout R, Mishra A, Kharfan-Dabaja MA (2016) Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. Hematol Oncol Stem Cell Ther 9(4):157–161PubMedGoogle Scholar
- 36.Cangemi G, Barco S, Bonifazio P, Maffia A, Agazzi A, Melioli G (2013) Comparison of antibody-conjugated magnetic immunoassay and liquid chromatography-tandem mass spectrometry for the measurement of cyclosporine and tacrolimus in whole blood. Int J Immunopathol Pharmacol 26(2):419–426PubMedGoogle Scholar
- 37.Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, Schmitt-Hoffman AH, Bruggemann RJM (2017) Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis 19(5):e12751Google Scholar
- 40.Rosenkranzkw H, PÜtter J (1976) The binding of clotrimazole to the proteins of human serum. Eur J Drug Metab Pharmacokinet 1(2):73–76Google Scholar
- 46.el-Dahshan KF, Bakr MA, Donia AF, Badr A-S, Sobh MA (2004) Co-administration of ketoconazole to tacrolimus-treated kidney transplant recipients: a prospective randomized study. Nephrol Dial Transplant 19 (6): 1613-1617Google Scholar
- 48.Winston DJ, Limaye AP, Pelletier S, Safdar N, Morris MI, Meneses K, Busuttil RW, Singh N (2014) Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant 14(12):2758–2764PubMedGoogle Scholar